DAFNA Capital Management’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-587,456
| Closed | -$11.8M | – | 91 |
|
|
2021
Q3 | $11.8M | Buy |
587,456
+76,700
| +15% | +$2.12M | 3.14% | 5 |
|
|
2021
Q2 | $19.1M | Sell |
510,756
-77,000
| -13% | -$2.36M | 3.99% | 3 |
|
|
2021
Q1 | $15M | Hold |
587,756
| – | – | 3.57% | 4 |
|
|
2020
Q4 | $12.9M | Buy |
587,756
+133,520
| +29% | +$2.94M | 3.85% | 5 |
|
|
2020
Q3 | $8.17M | Hold |
454,236
| – | – | 2.66% | 9 |
|
|
2020
Q2 | $11.5M | Buy |
454,236
+306,522
| +208% | +$6.6M | 3.33% | 5 |
|
|
2020
Q1 | $2.71M | Buy |
147,714
+29,400
| +25% | +$571K | 1.13% | 27 |
|
|
2019
Q4 | $2.61M | Hold |
118,314
| – | – | 0.89% | 26 |
|
|
2019
Q3 | $1.7M | Hold |
118,314
| – | – | 0.64% | 40 |
|
|
2019
Q2 | $1.86M | Sell |
118,314
-5,000
| -4% | -$68K | 0.7% | 39 |
|
|
2019
Q1 | $1.81M | Buy |
123,314
+4,814
| +4% | +$55.3K | 0.78% | 40 |
|
|
2018
Q4 | $1.27M | Hold |
118,500
| – | – | 0.63% | 42 |
|
|
2018
Q3 | $1.81M | Buy |
118,500
+8,500
| +8% | +$124K | 0.74% | 40 |
|
|
2018
Q2 | $1.35M | Buy |
+110,000
| New | +$1.38M | 0.63% | 43 |
|
|
2016
Q4 | – | Sell |
-119,300
| Closed | -$701K | – | 76 |
|
|
2016
Q3 | $701K | Hold |
119,300
| – | – | 0.49% | 50 |
|
|
2016
Q2 | $358K | Sell |
119,300
-1,300
| -1% | -$5.34K | 0.28% | 67 |
|
|
2016
Q1 | $646K | Hold |
120,600
| – | – | 0.56% | 51 |
|
|
2015
Q4 | $1.43M | Sell |
120,600
-2,900
| -2% | -$33.2K | 1.28% | 26 |
|
|
2015
Q3 | $1.01M | Buy |
123,500
+36,700
| +42% | +$424K | 1.01% | 30 |
|
|
2015
Q2 | $1.21M | Buy |
+86,800
| New | +$1.59M | 1.02% | 33 |
|
Other funds holding DRNA
DAFNA Capital Management's DRNA Position: Q4 2021 in Review
DAFNA Capital Management sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2021, closing a stake of 587,456 shares — an estimated $11.8M sold.
DAFNA Capital Management first reported a position in DRNA in Q2 2015 and held it in 20 quarters. The position peaked at $19.1M in Q2 2021. 1 fund tracked by Wall St. Rank holds DRNA as of Q4 2021.
- DAFNA Capital Management reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
- DAFNA Capital Management sold 587,456 Dicerna Pharmaceuticals, Inc. shares in Q4 2021, an estimated $11.8M.
- DAFNA Capital Management first reported a position in Dicerna Pharmaceuticals, Inc. in Q2 2015 and held it in 20 quarters.
- DAFNA Capital Management's Dicerna Pharmaceuticals, Inc. position peaked at $19.1M in Q2 2021.
- 1 fund tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2021.
Based on DAFNA Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.